2021
Cost-Effectiveness of Second-Line Therapies in Adult Patients with Chronic Immune Thrombocytopenia
Goshua G, Sinha P, Pischel L, Lee A, Cuker A. Cost-Effectiveness of Second-Line Therapies in Adult Patients with Chronic Immune Thrombocytopenia. Blood 2021, 138: 751. DOI: 10.1182/blood-2021-144819.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioChronic immune thrombocytopeniaOne-way deterministic sensitivity analysisPost-splenectomy sepsisTPO-RATPO-RA therapyImmune thrombocytopeniaOverall response rateTreatment pathwaysProbabilistic sensitivity analysesDeterministic sensitivity analysesResponse rateAdverse eventsASH guidelinesStandard second-line treatment optionSecond-line treatment optionSecond-line treatment strategiesEarly useComplete response rateSecond-line therapySevere septic shockThrombopoietin receptor agonistsSeptic shock mortalityHealth system perspectiveCost of surgery
2020
Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes
Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes. CHEST Journal 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.Peer-Reviewed Original ResearchConceptsCytokine release syndromeTocilizumab-treated patientsSevere diseaseRelease syndromeTocilizumab treatmentInflammatory biomarkersNonsevere diseaseSoluble IL-2 receptor levelsHigh-sensitivity C-reactive proteinIL-2 receptor levelsConsecutive COVID-19 patientsIL-6 receptor antagonistMechanical ventilation outcomesC-reactive proteinCOVID-19 patientsHigher admission levelsRace/ethnicityMV daysVentilation outcomesAdverse eventsChart reviewClinical responseMedian ageWhite patientsClinical outcomes